| 3.39 -0.16 (-4.51%) | 09-10 12:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.32 | 1-year : | 4.78 |
| Resists | First : | 3.69 | Second : | 4.09 |
| Pivot price | 3.88 |
|||
| Supports | First : | 3.04 | Second : | 2.53 |
| MAs | MA(5) : | 3.65 |
MA(20) : | 3.81  |
| MA(100) : | 3.25 |
MA(250) : | 4.95 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 46.7 |
D(3) : | 58 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 9.5 | Low : | 1.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NSRX ] has closed below the lower bollinger band by 10.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NSRX ] is to continue within current trading range. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.58 - 3.59 | 3.59 - 3.61 |
| Low: | 3.31 - 3.33 | 3.33 - 3.36 |
| Close: | 3.51 - 3.55 | 3.55 - 3.58 |
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Tue, 08 Sep 2026
Nasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment Conference - Quiver Quantitative
Tue, 08 Sep 2026
A company developing nasal allergy medicine will present in New York - Stock Titan
Tue, 08 Sep 2026
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance Singapore
Fri, 04 Sep 2026
A $750,000 sale bonus? Nasus Pharma (NSRX) puts CEO pay to a shareholder vote - Stock Titan
Tue, 01 Sep 2026
Nasus Pharma (NYSE: NSRX) sets $50M share shelf for working capital and drug development - Stock Titan
Wed, 19 Aug 2026
Nasus Pharma Announces Transition of Chief Financial Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|